1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. WOCKHARDT LTD.
Wockhardt Ltd.
NSE: WOCKPHARMA | BSE: 532300

Wockhardt Live Share Price Today, Share Analysis and Chart

Mid-range Performer
BasketIn 3 Starfolio Baskets
aboutWockhardt Ltd. is a global pharmaceutical and biotechnology company with a focused presence in drug discovery, manufacturing, and marketing. The company operates across multiple therapeutic areas, including anti-infectives, diabetes, cardiology, and ... Read More
US FDA InspectionsANDA Approvals
Ask AI about Wockhardt
1901.10-21.80(-1.13%)

74.94% Gain from 52W Low

544.5K
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for Wockhardt is on 02 Nov 2026 for the purpose of Quarterly Results See details
Loading...
- / 100
- / 100
51.1 / 100
Mid-range PerformerThese stocks have strong quality. Their reasonable financials and technicals make them potentially attractive to investorsView SimilarEmbed DVM
Analyst Price Target
No estimates available

17

S

9

W

2

O

1

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

Medium rank

11Positive12Negative

47.8%Pass in checklist

045
55
100

Check P/E Buy Sell Zone

Strong Sell Zone

81.0 %    into P/E buy sell zone

% time spent below current P/E
020406080100
Strong upside potential
Gains already realized

Wockhardt Stock Price Analysis

Day Price Range

-1.1% 1 Day return
1901.1 (LTP)
1,8721,932.9
LowHigh

Week Price Range

5.5% 1 Week return
1901.1 (LTP)
1,780.51,960.5
LowHigh

Month Price Range

-13.4% 1 Month return
1901.1 (LTP)
1,7722,213.6
LowHigh

52 Week Price Range

47.2% 1 Year return
1901.1 (LTP)
1,086.72,422.3
LowHigh
View full Price History/Seasonality

Wockhardt Technical Analysis

Wockhardt EMA & SMA

Bearish-4
2 bullish, 6 bearish
Bullish2
Bearish6
5 Day1896
10 Day1905.7
12 Day1914.7
20 Day1950.1
26 Day1967.9
50 Day1984.6
100 Day1924.1
200 Day1785.3

Wockhardt Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202638.3%
Week39.9%
Month40.6%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Wockhardt Resistance and Support

1902.00
Pivot
First Resistance1932
Second Resistance1962.9
Third Resistance1992.9
First Support1871.1
Second Support1841.1
Third Support1810.2
Day RSI43
Day MACD-53.2
Day MFI30
Day MACD Signal Line-49.7

Wockhardt Beta

1 Month1.2
1 Year1
3 Month1.4
3 Year1.2

Wockhardt Price Change Analysis

↓-13.4%
Over 1 Month
LowHigh
17722213.6
↓-0.2%
Over 3 Months
LowHigh
17722360
↑36.6%
Over 6 Months
LowHigh
13822422.3
↑47.3%
Over 1 Year
LowHigh
1086.72422.3
All Technicals →

Wockhardt Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Themisto Trustee Company Private LimitedPromoter65,765,14340.5 %
Rekha JhunjhunwalaPublic2,837,0051.8 %
Tata Mutual Fund - Tata Small Cap FundDii3,305,9022.0 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Wockhardt Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
NK SECURITIES RESEARCH PRIVATE LIMITEDBulkSell06 May 20261720.711,009,622NSE
NK SECURITIES RESEARCH PRIVATE LIMITEDBulkPurchase06 May 202617201,009,622NSE
GRAVITON RESEARCH CAPITAL LLPBulkSell01 Jan 2024456.72844,583NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase01 Jan 2024456.76844,583NSE
GRAVITON RESEARCH CAPITAL LLPBulkSell12 Dec 2023397.26979,549NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase12 Dec 2023397.13979,549NSE
GRAVITON RESEARCH CAPITAL LLPBulkSell11 Dec 2023372.83916,319NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase11 Dec 2023373.22916,319NSE
GRAVITON RESEARCH CAPITAL LLPBulkSell17 Nov 2023325.171,148,101NSE
GRAVITON RESEARCH CAPITAL LLPBulkPurchase17 Nov 2023324.811,148,101NSE
All deals
All insider trades

Wockhardt Corporate Actions

Wockhardt Dividend history and yield

Wockhardt dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Wockhardt dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
117 Nov 2016
10INTERIM19 Nov 2016Equity Share
213 Nov 2014
20INTERIM15 Nov 2014Equity Share
317 Feb 2014
5INTERIM19 Feb 2014Equity Share
407 Nov 2013
5INTERIM08 Nov 2013Equity Share
522 Aug 2013
5FINAL-Equity Share

Wockhardt Bonus shares

Wockhardt bonus history along with announcement, record, ex-bonus dates, and bonus ratios.

#Ex-Date
Bonus RatioRecord Date
128 Apr 2004
1:2-

Wockhardt Board Meetings

Wockhardt past and upcoming board meetings.

#Ex-Date
PurposeNotes
102 Nov 2026
Quarterly Results-
210 Aug 2026
Quarterly Results-
304 May 2026
Audited Results & OthersInter-alia, to consider 1. Raising of funds by issue of Equity Shares, American Depository Receipts , Foreign Currency Convertible Bonds or any combination thereof or any other method.
410 Feb 2026
Quarterly Results-
503 Nov 2025
Quarterly Results-

Wockhardt Stock Split

Wockhardt stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date
Old FVNew FVRecord Date
128 Apr 2004
105-

Wockhardt Rights issue

Wockhardt rights issue history, along with record, ex-rights dates, and rights ratios.

#Ex-Date
RatioFace ValuePremiumRecord Date
108 Mar 2022
3.0:10.0522009 Mar 2022
All Corporate Actions

Wockhardt Research Reports

Wockhardt research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
111 Jun 2026Deven Choksey-1938Not Rated--1.9%pdf
207 Jul 2025Axis Direct18701657.8Buy12.8%14.68%pdf
331 Jan 2018HDFC Securities-804.75Results Update-136.23%pdf
423 May 2017HDFC Securities-617.45Results Update-207.9%pdf
531 Jan 2017HDFC Securities-647.3Results Update-193.7%pdf
All Reports of Wockhardt

Wockhardt Corporate Filings

Wockhardt BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
27 Oct 2026
Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
We wish to inform that Share Allotment Committee of Board of Directors of the Company has allotted 20000 equity shares of face value of Rs 5 each on 27th October, 2026 pursuant to exercise of Stock options under Employee Stock Options Scheme- 2011 of the Company.
PDF
27 Oct 2026
Wockhardt Ltd - 532300 - Board Meeting Intimation for Intimation Of The Meeting Of Board Of Directors Of Wockhardt Limited ('The Company')
Wockhardt Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company will be held on Monday, 2nd November, 2026, inter-alia, to consider and approve the Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended 30th September, 2026.
PDF
24 Oct 2026
Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 read with Schedule III Part A Para A of the SEBI (LODR) Regulations, 2015, we enclose herewith a copy of newspaper advertisement regarding the opening of special window for re-lodgement of the transfer requests of share held in physical form.
PDF
09 Oct 2026
Wockhardt Ltd - 532300 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find attached the Certificate received from MUFG Intime India Private Limited, Registrar and Share Transfer Agent of the Company for the quarter 30th September, 2026
PDF
25 Sep 2026
Wockhardt Ltd - 532300 - Closure of Trading Window
The Trading Window for dealing in the equity shares of the Company will be closed from 1st October, 2026 until 48 hours after the declaration of Unaudited financial results for quarter and half year ended 30th September, 2026.
PDF
VIEW ALL

Wockhardt DocumentsAsk MarketMind AI

Wockhardt Earnings Call

Wockhardt earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
11 Jun 2026Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
11 Jun 2025Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAi summaryLink
24 Feb 2023WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
21 Feb 2023Wockhardt Results Earnings Call for Q3FY23AudioVideo
03 Feb 2020Earnings Call Transcript - Wockhardt Ltd.Link
view all

Wockhardt Annual Reports

Wockhardt financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link

Wockhardt Credit Ratings

Wockhardt credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
20 May 2026icra ratingsWockhardt LimitedRatings upgraded; outlook revised to Stable; assigned for the enhanced amountLink
25 Aug 2025icra ratingsWockhardt LimitedRatings upgraded; outlook revised to PositiveLink
29 Aug 2024care ratingsWockhardt LimitedLink
14 May 2024icra ratingsWockhardt Limited[ICRA]BBB-(Stable)/[ICRA]A3; assignedLink
09 Oct 2023india ratingsIndia Ratings Downgrades Wockhardt to ‘IND B+(ISSUER NOT COOPERATING)’/NegativeLink

Wockhardt Investor Presentations

Wockhardt investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
04 Jun 2026Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
05 Jun 2025Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
05 Jun 2025Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
21 Oct 2024WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
26 Feb 2024WOCKHARDT LTD. - 532300 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Wockhardt - Company Profile

Wockhardt Management Structure

Wockhardt management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Mr. Sunil SoniSenior Vice President-Mar 26
Mr. Paresh KajrolkarChief Risk Officer,Global Chief Internal Auditor,Chief Sustainability OFficer-Mar 26
Dr. Sanjeev Kumar SharmaPresident(Manufacturing,Quality,R&D)-Mar 26
Mr. Satej MehtaHead(Human Resources)-Mar 26
Mr. Jagmohan RishiHead(Training & Development)-Mar 26
Mr. Avijit DebChief Digital Officer-Mar 26
Mr. Sailesh TekriwalHead(Supply Chain.,Distribution)-Mar 26
Mr. Viren SharmaAdvisor(Consultant ESG)-Mar 26
Mr. Deepak Rajkumar MadnaniChief Financial Officer-Mar 26
Rashmi MamturaCompany Secretary,Compliance Officer-Mar 26
Mrs. Debolina PartapSenior Vice President-Mar 26
Dr. Sachin BhagwatChief Scientific Officer-Mar 26
Ms. Annapurna DasPresident(Business Unit)-Mar 26
Mr. Om NarayanSenior Vice President-Mar 26

Wockhardt Board of Directors

Wockhardt Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
H F KhorakiwalaChairman & Exec. Director500Mar 26
Huzaifa H KhorakiwalaExecutive Director281Mar 26
Murtaza H KhorakiwalaExecutive Director & MD281Mar 26
Vineshkumar JairathIndependent Non Exe. Director14Mar 26
Ahmad JavedIndependent Non Exe. Director14Mar 26
Akhilesh Krishna GuptaIndependent Non Exe. Director12Mar 26
Amelia FernandesIndependent Non Exe. Director11Mar 26
O P BhattIndependent Non Exe. Director5Mar 26
Zahabiya Habil KhorakiwalaNon-Exec & Non-Independent Dir4Mar 26
Rashmi MamturaCompany Sec. & Compli. Officer-Mar 26
Website: www.wockhardt.com

About the company - Business Profile

Wockhardt Ltd. is a global pharmaceutical and biotechnology company with a focused presence in drug discovery, manufacturing, and marketing. The company operates across multiple therapeutic areas, including anti-infectives, diabetes, cardiology, and dermatology. Wockhardt is recognized for its dedicated research in novel antibiotics, aiming to address the global challenge of antimicrobial resistance (AMR). The company maintains a significant international footprint, particularly in the UK, USA, and Europe, which together contribute a substantial portion of its total consolidated revenue.

Key Points

  • Key Facts: Founded in 1967 by Dr. Habil Khorakiwala, Wockhardt is headquartered in Mumbai, India. It is a publicly-traded company listed on both the BSE and NSE. The group is a research-based global healthcare enterprise with 26 overseas subsidiaries as of 2024.
  • Operations and Resources: Wockhardt operates 12 manufacturing plants across India, the UK, Ireland, and the USA. Its Indian facilities are located in Maharashtra (Waluj, Chikalthana, Shendra), Daman, and Gujarat (Ankleshwar). International sites include Wrexham (UK), Clonmel (Ireland), and Dubai (UAE).
  • Ownership and Significance: The company remains promoter-led, with the Khorakiwala family holding a majority stake. It plays a critical role in the global supply of essential medicines, particularly in the UK where it is a major supplier to the National Health Service (NHS).
  • Business Model: Wockhardt follows an integrated business model encompassing R&D, manufacturing, and distribution. It specializes in developing complex generics and New Chemical Entities (NCEs). Its core strength lies in its anti-infective R&D pipeline, which has received multiple Qualified Infectious Disease Product (QIDP) designations from the US FDA.
  • Financial Highlights (FY25 Annualized/Actuals):
    • Total Income: Rs 3,074 crore for FY 2024-25.
    • Operating Profit (EBITDA): Rs 418 crore for FY 2024-25.
    • International Business: Contributed 78% of the total revenue in FY 2024-25.
    • Revenue by Geography (FY24): USA (13%), UK (35%), India (19%), Rest of World (33%).
  • Key Products and R&D:
    • Antibiotic Pipeline: Focused on MDR (multi-drug resistant) bacterial pathogens. Notable candidates include WCK 5222 (Zidovudine/Nulibactam), WCK 4873 (Nafithromycin), and WCK 5107.
    • Biologics: Significant capabilities in insulin and biosimilar production.
  • Strategic Initiatives:
    • De-leveraging: The company has focused on reducing debt, achieving a Net Debt to Equity ratio of 0.27 in FY 2024-25.
    • Antibiotic Commercialization: Active pursuit of clinical trials and regulatory approvals for its novel antibiotic pipeline in global markets.
    • Restructuring: Divestment of non-core assets and segments to focus on high-growth R&D-driven areas.
  • Employee Count and Global Presence: The company employs a diverse workforce comprising 27 nationalities with research and manufacturing hubs spread across multiple continents.

References

  1. Annual Report May 2025
  2. Annual Report May 2024
  3. Quarterly Results Feb 2026
  4. Quarterly Results Nov 2025

Wockhardt FAQ

Wockhardt today is trading in the red, down by 1.13% at ₹1,901.1.
Wockhardt is currently trading down 1.13% on an intraday basis. In the past week the stock rose 5.52%. Stock has been down 0.15% in the past quarter and rose 47.25% in the past year. You can view this in the share price history/seasonality section.
Wockhardt is listed on NSE with the ticker WOCKPHARMA and on BSE as 532300. It's currently trading on NSE at a share price of ₹1,901.1 and on BSE with a share price of ₹1,871.
The market cap of Wockhardt is ₹30,895.19 Cr. as of Oct 30, 2026.
Wockhardt announced a INTERIM dividend of 200% which equals ₹10 in Nov 17, 2016.The last three ex-dates for Wockhardt were Nov 13, 2014, Feb 17, 2014 and Nov 07, 2013. To view the full dividend history of Wockhardt click here.
Wockhardt has undergone 1 stock split and announced bonus shares 1 time since its BSE/NSE listing. The latest announcement for Wockhardt stock split was on Apr 28, 2004 at a ratio of 10:5 and the last bonus share announcement was on Apr 28, 2004 at a ratio of 1:2.
Wockhardt reported ₹960 Cr. in revenue, ₹106 Cr. in net profit, and ₹223 Cr. in EBITD as of Aug 10, 2026 for Q1 FY26-27.
There are no analyst predictions for stock price target for Wockhardt.
The PE ratio of Wockhardt is 75.54 as of Oct 30, 2026.
The PB ratio of Wockhardt is 6.12 as of Oct 30, 2026.
You can view the latest analyst reports on the Wockhardt reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×